IMVT vs CYTK
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
IMVT · Immunovant$31.77 ▼ 2.31%
CYTK · Cytokinetics$50.78 ▼ 1.32%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- IMVT +36.2%
- CYTK -24.4%
Head to head
| Metric | IMVT | CYTK |
|---|---|---|
| Price | $31.77 | $50.78 |
| Change today | ▼ 2.31% | ▼ 1.32% |
| Market cap | $6.57B | $7.07B |
| Return, 3 months | -26.7% | -34.1% |
| Return, year to date | +25.0% | -20.1% |
| Return, 1 year | +40.6% | -22.4% |
| P/E (TTM) | – | – |
| P/B | 10.0 | -22.0 |
| P/E percentile vs own 5y | 28th | 65th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | +2,356.5% |
| Net profit growth (YoY) | +23.1% | +37.9% |
| Gross margin | – | 95.3% |
| Operating margin | – | -625.2% |
| Net margin | – | -686.6% |
| Return on equity | -86.5% | – |
| Analyst target vs. price | +52.4% | +111.3% |
| Analyst buy share | 75% | 94% |
| RSI (14) | 48 | 30 |
| 30-day volatility | 62.7% | 52.6% |
| Max drawdown, 1 year | -40.5% | -41.8% |
| Trend read | Leaning bearish | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- CYTK is the largest of the group by market value.
- IMVT has returned the most over the past year.
- CYTK has been the calmest stock over the last 30 days.